AFFITOPE® PD01A + Adjuvant

BIOLOGICAL2 trials

Sponsors

Affiris AG

Conditions

Multiple System AtrophyNeurodegenerative DiseasesParkinson's Disease

Phase 1

Study Assessing Safety and Therapeutic Activity of AFFITOPE® PD01A and PD03A in Patients With Early MSA

CompletedNCT02270489

Affiris AGMultiple System Atrophy, Neurodegenerative Diseases

Start: 2014-12-11End: 2017-04-18Updated: 2017-06-05

Study Assessing Tolerability and Safety and Exploring the Immunogenicity and Therapeutic Activity of AFFITOPE® PD01A in PD-GBA Patients

WithdrawnNCT02758730

Affiris AGParkinson's Disease

Updated: 2016-08-05

Related Papers

A Phase 1 Randomized Trial of Specific Active <scp>α‐Synuclein</scp> Immunotherapies <scp>PD01A</scp> and <scp>PD03A</scp> in Multiple System Atrophy

Movement Disorders2020-09-0378 citations

Antibody-based immunotherapies for Parkinsonian syndromes

Neural Regeneration Research2019-01-014 citations